ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0002258

pharyngitis

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. pharyngitis. Diseases, record MONDO_0002258. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002258

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
pharyngitis
Open Targets
Open Targets ID
MONDO_0002258
Open Targets
Other names
Sore throat, inflammation of throat, throat inflammation
Open Targets
Disease Ontology
DOID:2275
Disease Ontology
MeSH
D010612
MeSH
NCI Thesaurus
C26851
NCI Thesaurus
Highest stage of its drugs
Approval, for 24 of its 44 drugs, from DailyMed and PMDA
Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
AMOXICILLINCHEMBL1082Small moleculeApprovalDailyMed322Drugs and targets
MENTHOLCHEMBL256087Small moleculeApprovalDailyMed2011Drugs and targets
AZITHROMYCINCHEMBL529Small moleculeApprovalDailyMed1111Drugs and targets
TELITHROMYCINCHEMBL1136Small moleculeApprovalEMA Human Drugs, at withdrawal311Drugs and targets
CLARITHROMYCINCHEMBL1741Small moleculeApprovalDailyMed211Drugs and targets
ACETAMINOPHENCHEMBL112Small moleculeApprovalDailyMed3600Drugs and targets
DEXTROMETHORPHAN HYDROBROMIDECHEMBL1256818Small moleculeApprovalDailyMed2900Drugs and targets
PHENYLEPHRINE HYDROCHLORIDECHEMBL1200339Small moleculeApprovalDailyMed1800Drugs and targets
CEFACLORCHEMBL1201018Small moleculeApprovalDailyMed1200Drugs and targets
CEFIXIMECHEMBL1541Small moleculeApprovalDailyMed900Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
PTGS2Cyclooxygenase7Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitorApprovalhttps://conductscience.org/library/genes/5743Drugs and targets
PTGS1Cyclooxygenase5Cyclooxygenase inhibitorApprovalhttps://conductscience.org/library/genes/5742Drugs and targets
HRH1Histamine H1 receptor3Histamine H1 receptor antagonistApprovalhttps://conductscience.org/library/genes/3269Drugs and targets
GRIN2AGlutamate [NMDA] receptor2Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonistApprovalhttps://conductscience.org/library/genes/2903Drugs and targets
NR3C1Glucocorticoid receptor2Glucocorticoid receptor agonistPhase 2/3https://conductscience.org/library/genes/2908Drugs and targets
ADRA1AAdrenergic receptor alpha-11Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/148Drugs and targets
ADRA1BAdrenergic receptor alpha-11Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/147Drugs and targets
ADRA1DAdrenergic receptor alpha-11Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/146Drugs and targets
ADRA2AAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 3https://conductscience.org/library/genes/150Drugs and targets
ADRA2BAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 3https://conductscience.org/library/genes/151Drugs and targets

1 to 10 of 35

See all 35 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00402987Testing The Effectiveness Of Celecoxib In Patients With Painful Sore ThroatPhase 32692009-03-12PharyngitisCELECOXIBIts record names the diseaseClinicalTrials.gov
NCT01265446Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.Phase 32502012-07-26Sore Throat Due to a Common ColdCETYLPYRIDINIUM CHLORIDE, LIDOCAINEIts record names the diseaseClinicalTrials.gov
NCT03095508
Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat
Phase 32292019-03-21Sore Throat(+)-MENTHOL, MENTHOLIts record names the diseaseClinicalTrials.gov
NCT01048866A Study of Flurbiprofen 8.75 mg Lozenge in Patients With PharyngitisPhase 31982017-09-21PharyngitisFLURBIPROFENIts record names the diseaseClinicalTrials.gov
NCT01986361Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch MethodPhase 31222017-08-24Acute Pharyngitis, Sore ThroatFLURBIPROFENIts record names the diseaseClinicalTrials.gov
NCT01919996PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric PatientsPhase 282016-07-06Pharyngitis, TonsillitisAZITHROMYCINIts record names the diseaseClinicalTrials.gov
NCT01361399Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common ColdPhase 31,088Common Cold, Pharyngitis, TonsillitisASPIRIN, LIDOCAINEIts record names the diseaseClinicalTrials.gov
NCT01062360Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus PseudoephedrinePhase 31,016Common Cold, PharyngitisASPIRIN, PSEUDOEPHEDRINEIts record names the diseaseClinicalTrials.gov
NCT00170001Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) TherapyNot applicable500Gastroesophageal RefluxESOMEPRAZOLEIts record names the diseaseClinicalTrials.gov
NCT01406275Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)363Otitis MaediaAMOXICILLIN, CLAVULANIC ACIDIts record names the diseaseClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Lidocaine 8mg +CPC 2mg vs Lidocaine 1mg + CPC 2mg: serious adverse events1 of 1250 of 125250NCT01265446Trial comparisons
Angal S (Arm A) vs ANTI-ANGIN® FORMULA (Arm B): Number of Participants Who Fully Recovered106 of 114107 of 115229NCT03095508Trial comparisons
Angal S (Arm A) vs ANTI-ANGIN® FORMULA (Arm B): deaths from any cause0 of 1140 of 115229NCT03095508Trial comparisons
Angal S (Arm A) vs ANTI-ANGIN® FORMULA (Arm B): serious adverse events0 of 1140 of 115229NCT03095508Trial comparisons
Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge: serious adverse events0 of 1010 of 97198NCT01048866Trial comparisons
Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge: serious adverse events0 of 1010 of 21122NCT01986361Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
28931508RESULT1PubMed
28418482RESULT1PubMed
23076943RESULT1PubMed
18958997RESULT1PubMed
17597571RESULT1PubMed
17148626RESULT1PubMed
16504956RESULT1PubMed
15556647RESULT1PubMed
14526713RESULT1PubMed
8628614RESULT1PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002258

GET https://conductscience.org/api/diseases/v1/MONDO_0002258/drugs?page=2

API referenceFor AI assistants